Dasatinib

Where the papers sit

16 papers from the last 6 months study dasatinib directly · updated from PubMed 12 Oct 2026

• Chronic Myeloid Leukemia Care

  Dasatinib care in chronic myeloid leukemia is moving toward response-adapted dosing rather than uniform long-term exposure. BCR::ABL1 decline velocity and prospective de-escalation studies are testing whether selected patients can receive less intensive therapy while maintaining molecular control. Echocardiography and arterial-stiffness monitoring address cardiovascular risk, while proton pump inhibitors and transporter interactions may drive treatment switching. Nilotinib and asciminib provide alternative TKI contexts, but durable response with less toxicity remains the central goal.

  7 papers · 43.8%

• Targeted Cancer Therapy

  Targeted cancer therapy is being pursued through localized drug delivery and pathway-directed radiotherapy combinations. An albumin nanoparticle-loaded hydrogel is designed to eradicate residual melanoma, with EGFR, mTOR and VEGFR2 among the nominated targets. The BIOMEDE trial tests targeted agents with radiotherapy in diffuse intrinsic pontine glioma, bringing clinical outcome assessment to this strategy. The shared direction is combining pathway inhibition with radiotherapy or spatially focused exposure, although the studies span distinct cancers and evidence levels.

  2 papers · 12.5%

• Others — Cellular Senescence Biology

  Cellular senescence is linked to impaired hematopoietic stem-cell function, muscle atrophy, osteoarthritis and insulin resistance. Quercetin and uPAR/PLAUR-directed strategies point toward reducing senescent-cell burden, while dasatinib also alters T-cell motility and activation. Other entries address BH3-mimetic sensitivity, pan-cancer prognostic biomarkers and drug synergy in lung cancer. The group shares senescence and cancer-signaling themes but lacks one unified therapeutic direction.

  7 papers · 43.8%